RhumbLine Advisers
ATHE

RhumbLine Advisers’s Alterity Therapeutics ATHE Stock Holding History

RhumbLine Advisers’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Buy
2,009
+39
+2% +$170 ﹤0.01% 3890
2026
Q1 		$7.01K Sell
1,970
-157
-7% -$532 ﹤0.01% 3841
2025
Q4 		$6.55K Buy
2,127
+1,241
+140% +$4.74K ﹤0.01% 3907
2025
Q3 		$3.34K Buy
886
+756
+582% +$3.65K ﹤0.01% 3943
2025
Q2 		$533 Hold
130
– – ﹤0.01% 4071
2025
Q1 		$450 Buy
+130
New +$498 ﹤0.01% 4061

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PCA
Providence Capital Advisors Charlotte, North Carolina $660M AUM 17.81% 1-Year Est. Return

RhumbLine Advisers's ATHE Position: Q2 2026 in Review

RhumbLine Advisers increased its Alterity Therapeutics (ATHE) stake by 2% in Q2 2026, buying an estimated $170 and bringing the position to 2,009 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3890.

RhumbLine Advisers first reported a position in ATHE in Q1 2025 and has held it in 6 quarters since. 22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • RhumbLine Advisers held 2,009 shares of Alterity Therapeutics worth $10.8K as of Q2 2026.
  • RhumbLine Advisers bought 39 Alterity Therapeutics shares in Q2 2026, an estimated $170.
  • Alterity Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3890 holding.
  • RhumbLine Advisers first reported a position in Alterity Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.